No Data
Two Sessions Time | National People's Congress Representative, Lu Qingguo from Chenguang Biotech Group: Improve the quality standards of Chinese Patent Medicine, regulate the centralized procurement model for Traditional Chinese Medicine, and optimize the
① Lu Qingguo, Director of Chenguang Biotech Group and a representative of the National People's Congress, focused on several recommendations at this year's Two Sessions, including optimizing the procurement mechanism for Traditional Chinese Medicine, enhancing the quality standards for Chinese Patent Medicine, and standardizing the Traditional Chinese Medicine granule industry; ② In addition to recommendations related to the Traditional Chinese Medicine industry, Lu Qingguo prepared several suggestions on rural social retirement insurance, rural medical insurance, and increasing support for companies sanctioned by the United States.
Jinling Pharmaceutical (000919.SZ): has noted the impact of AI applications on the pharmaceutical Industry and will study relevant possible applications according to needs and industry development conditions.
Gelonghui, February 24th丨Jinling Pharmaceutical (000919.SZ) stated on the investor interaction platform that the company has paid attention to the impact of AI applications on the pharmaceutical Industry and will study relevant possible applications as needed and according to the development status of the Industry.
Jinling Pharmaceutical (000919.SZ): Currently, there is no relevant data on Assets.
Gelonghui reported on February 20 that Jinling Pharmaceutical (000919.SZ) stated on the investor interaction platform that the company currently has no relevant data assets.
Overview of the lifting of restrictions on trading A-shares | February 17.
According to the Zhitong Finance APP, on February 17, a total of 19 listed companies have unlocked their restricted shares, with a total market value of approximately 6.288 billion yuan. Today's specific situation of the unlocked restricted shares is as follows: Stock Abbreviation Stock Code Restricted Share Type Unlocked Share Number Luzhou Laojiao 000568 Stock-based Incentive 0.0371 million Jinling Pharmaceutical 000919 Stock-based Incentive 1.92 million Hubei Guangji Pharmaceutical 000952 Stock-based Incentive 2.5209 million JiangSu WuZhong Pharmaceutical Development 600200 Stock-based Incentive 0.9612 million China National Software & Service 600536 Stock-based Incentive 0.0572 million Shinva Medical Instrument 6005
Jinling Pharmaceutical: Jinling Pharmaceutical Co., Ltd. 2024 Annual Performance Forecast
Jinling Pharmaceutical (000919.SZ): The subsidiary involved in Retirement business currently mainly adopts the Institutions Retirement Operation model.
On January 8, Gelonghui reported that Jinling Pharmaceutical (000919.SZ) stated on the investor interaction platform that its subsidiary, which is involved in Retirement Business, mainly adopts an Institutional Retirement model for Operation. The Hefei Jinling Tianyi Smart Retirement project under construction plans to utilize a smart health retirement model to provide customers with intelligent elderly living, smart health management, intelligent Leisure experiences, and other retirement and rehabilitation services. It also plans to offer home-based retirement services in accordance with national policies and market-oriented Operation models.
Investors One-year Losses Continue as Jinling Pharmaceutical (SZSE:000919) Dips a Further 10% This Week, Earnings Continue to Decline
